Correction to: Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
Works matching IS 11753277 AND DT 2022 AND VI 22 AND IP 1
Results: 14
1
2
Correction to: Comparative Real-Life Effectiveness and Safety of Dabigatran or Rivaroxaban vs. Vitamin K Antagonists: A High-Dimensional Propensity Score Matched New Users Cohort Study in the French National Healthcare Data System SNDS.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
3
Correction to: A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
4
Correction to: Dapaglifozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction.
- Published in:
- 2022
- By:
- Publication type:
- Correction Notice
5
Proposed Pathogenesis, Characteristics, and Management of COVID-19 mRNA Vaccine-Related Myopericarditis.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 9, doi. 10.1007/s40256-021-00511-8
- By:
- Publication type:
- Article
6
A Review of the Clinical Pharmacology of Pelacarsen: A Lipoprotein(a)-Lowering Agent.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 47, doi. 10.1007/s40256-021-00499-1
- By:
- Publication type:
- Article
7
SGLT2 Inhibitors: The Dawn of a New Era in Cardio-Metabolic Therapeutics.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
8
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 93, doi. 10.1007/s40256-021-00491-9
- By:
- Publication type:
- Article
9
The Cost Implications of Dabigatran in Patients with Myocardial Injury After Non-Cardiac Surgery.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 83, doi. 10.1007/s40256-021-00489-3
- By:
- Publication type:
- Article
10
Diabetes, Heart Failure and Beyond: Elucidating the Cardioprotective Mechanisms of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 35, doi. 10.1007/s40256-021-00486-6
- By:
- Publication type:
- Article
11
Comparative Efficacy of Five SGLT2i on Cardiorenal Events: A Network Meta-analysis Based on Ten CVOTs.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 69, doi. 10.1007/s40256-021-00484-8
- By:
- Publication type:
- Article
12
A Brief Overview of Recurrent Pericarditis Management and the Potential of Rilonacept as a New Therapeutic Option.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 27, doi. 10.1007/s40256-021-00481-x
- By:
- Publication type:
- Article
13
Evolocumab's Long-Term Mortality Risk Unclear Due to Shortened Follow-Up of FOURIER.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 5, doi. 10.1007/s40256-021-00480-y
- By:
- Publication type:
- Article
14
Management of Acute Coronary Syndrome in Patients with Liver Cirrhosis.
- Published in:
- American Journal of Cardiovascular Drugs, 2022, v. 22, n. 1, p. 55, doi. 10.1007/s40256-021-00478-6
- By:
- Publication type:
- Article